🚀 VC round data is live in beta, check it out!
Ipca Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ipca Laboratories and similar public comparables like NewAmsterdam Pharma, Livzon Pharmaceutical Group, Indivior Pharmaceuticals, Hualan Biological Engineering and more.
Ipca Laboratories Overview
About Ipca Laboratories
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Founded
1949
HQ
Employees
18.0K
Website
Sectors
Financials (LTM)
EV
$4B
Ipca Laboratories Financials
Ipca Laboratories reported last 12-month revenue of $1B and EBITDA of $215M.
In the same LTM period, Ipca Laboratories generated $726M in gross profit, $215M in EBITDA, and $125M in net income.
Revenue (LTM)
Ipca Laboratories P&L
In the most recent fiscal year, Ipca Laboratories reported revenue of $1B and EBITDA of $201M.
Ipca Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $726M | XXX | $637M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $215M | XXX | $201M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $125M | XXX | $116M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $122M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ipca Laboratories Stock Performance
Ipca Laboratories has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Ipca Laboratories' stock price is $15.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 0.8% | XXX | XXX | XXX | $0.46 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIpca Laboratories Valuation Multiples
Ipca Laboratories trades at 3.8x EV/Revenue multiple, and 18.6x EV/EBITDA.
EV / Revenue (LTM)
Ipca Laboratories Financial Valuation Multiples
As of April 18, 2026, Ipca Laboratories has market cap of $4B and EV of $4B.
Equity research analysts estimate Ipca Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ipca Laboratories has a P/E ratio of 32.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 18.6x | XXX | 20.0x | XXX | XXX | XXX |
| EV/EBIT | 23.3x | XXX | 25.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.5x | XXX | 6.3x | XXX | XXX | XXX |
| P/E | 32.1x | XXX | 34.5x | XXX | XXX | XXX |
| EV/FCF | 43.7x | XXX | 67.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ipca Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ipca Laboratories Margins & Growth Rates
Ipca Laboratories' revenue in the last 12 month grew by 11%.
Ipca Laboratories' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Ipca Laboratories' rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ipca Laboratories' rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ipca Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ipca Laboratories Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ipca Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| NewAmsterdam Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Livzon Pharmaceutical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Indivior Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Engineering | XXX | XXX | XXX | XXX | XXX | XXX |
| Tianjin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ipca Laboratories M&A Activity
Ipca Laboratories acquired XXX companies to date.
Last acquisition by Ipca Laboratories was on XXXXXXXX, XXXXX. Ipca Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ipca Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIpca Laboratories Investment Activity
Ipca Laboratories invested in XXX companies to date.
Ipca Laboratories made its latest investment on XXXXXXXX, XXXXX. Ipca Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ipca Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ipca Laboratories
| When was Ipca Laboratories founded? | Ipca Laboratories was founded in 1949. |
| Where is Ipca Laboratories headquartered? | Ipca Laboratories is headquartered in India. |
| How many employees does Ipca Laboratories have? | As of today, Ipca Laboratories has over 18K employees. |
| Who is the CEO of Ipca Laboratories? | Ipca Laboratories' CEO is Pranay Godha. |
| Is Ipca Laboratories publicly listed? | Yes, Ipca Laboratories is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Ipca Laboratories? | Ipca Laboratories trades under IPCALAB ticker. |
| When did Ipca Laboratories go public? | Ipca Laboratories went public in 1995. |
| Who are competitors of Ipca Laboratories? | Ipca Laboratories main competitors are NewAmsterdam Pharma, Livzon Pharmaceutical Group, Indivior Pharmaceuticals, Hualan Biological Engineering. |
| What is the current market cap of Ipca Laboratories? | Ipca Laboratories' current market cap is $4B. |
| What is the current revenue of Ipca Laboratories? | Ipca Laboratories' last 12 months revenue is $1B. |
| What is the current revenue growth of Ipca Laboratories? | Ipca Laboratories revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Ipca Laboratories? | Current revenue multiple of Ipca Laboratories is 3.8x. |
| Is Ipca Laboratories profitable? | Yes, Ipca Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ipca Laboratories? | Ipca Laboratories' last 12 months EBITDA is $215M. |
| What is Ipca Laboratories' EBITDA margin? | Ipca Laboratories' last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Ipca Laboratories? | Current EBITDA multiple of Ipca Laboratories is 18.6x. |
| What is the current FCF of Ipca Laboratories? | Ipca Laboratories' last 12 months FCF is $92M. |
| What is Ipca Laboratories' FCF margin? | Ipca Laboratories' last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Ipca Laboratories? | Current FCF multiple of Ipca Laboratories is 43.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.